Real-Time Clinical Data Insights Delivered by Automation and AI

Clinical trials generate unprecedented volumes of complex data across multiple systems, vendors, and sites. As regulatory expectations evolve under ICH E6(R3), sponsors are increasingly required to demonstrate continuous, traceable oversight of clinical trial data, not simply report outcomes at the end of a study.

Traditional spreadsheet-based workflows and fragmented review environments make this increasingly difficult. Manual reconciliation, delayed listings, and programming bottlenecks slow risk detection and limit the ability to document oversight decisions clearly.

This whitepaper explores how automation and governed AI can enable real-time, analytics-driven clinical oversight while preserving regulatory defensibility.

Inside the paper, you will learn:

Why manual, spreadsheet-based review workflows are increasingly difficult to sustain under modern oversight expectations

How automation and AI enable faster, more proactive monitoring of clinical data

How modern oversight platforms support ALCOA+ data integrity through traceable analytics, audit trails, and documented review workflows

Practical strategies sponsors and CROs are using to operationalize ICH E6(R3) requirements

How Signals Clinical™ supports earlier risk detection and inspection-ready oversight

Download the whitepaper to learn how clinical teams can move from reactive data review to continuous, compliance-ready oversight without increasing operational burden.